Hikma Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hikma Pharmaceuticals plc
The European Medicines Agency has recommended in favor of approval for Amarin’s fish-oil derivative, Vazkepa.
With an approval nod from the EMA’s scientific committee for its fish oil product Vazkepa, launch plans for the EU for this “multi-billion dollar” opportunity are on track, says Amarin CEO.
With operations in the MENA region already tracking to $700m in revenues for 2020, Hikma is looking to grow the business further after beginning negotiations with GSK to buy certain of the originator’s businesses in Egypt and Tunisia.
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- EIMC United Pharmaceuticals
- Roxane Laboratories, Inc.
- West-Ward Pharmaceuticals Corp.